Literature DB >> 25547437

Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy.

Konstantinos N Fountoulakis1, Xenia Gonda, Thomas C Baghai, David S Baldwin, Michael Bauer, Pierre Blier, Wagner Gattaz, Gregor Hasler, Hans-Jürgen Möller, Rajiv Tandon, Eduard Vieta, Siegfried Kasper.   

Abstract

INTRODUCTION: This report from the World Psychiatric Association Section on Pharmacopsychiatry examines the possible relationship of antiepileptic drugs with suicide-related clinical features and behaviors in patients with epilepsy.
MATERIALS AND METHODS: A systematic review of the MEDLINE search returned 1039 papers, of which only 8 were considered relevant. A critical analysis of the Food and Drug Administration (FDA) report on the increase risk for patients under antiepileptics to manifest suicidality is also included in this report.
RESULTS: The analysis of these studies revealed that the data are not supportive of the presence of a "class effect" on suicide-related behavior; on the contrary, there are some data suggesting such an effect concerning treatment with topiramate, lamotrigine, and levetiracetam for which further research is needed. DISCUSSION: For the majority of people with epilepsy, anticonvulsant treatment is necessary and its failure for any reason is expected to have deleterious consequences. Therefore, clinicians should inform patients and their families of this increased risk of suicidal ideation and behavior, but should not overemphasize the issue. Specific subgroups of patients with epilepsy might be at a higher risk, and deserve closer monitoring and follow-up. Future research with antiepileptics should specifically focus on depression and suicidal thoughts.

Entities:  

Keywords:  Antiepileptics; anticonvulsants; suicidality

Mesh:

Substances:

Year:  2015        PMID: 25547437     DOI: 10.3109/13651501.2014.1000930

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  6 in total

Review 1.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 2.  Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-09       Impact factor: 5.285

3.  Use and safety of antiepileptic drugs in psychiatric inpatients-data from the AMSP study.

Authors:  Katrin Druschky; Stefan Bleich; Renate Grohmann; Rolf R Engel; Alexandra Kleimann; Susanne Stübner; Waldemar Greil; Sermin Toto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-08-01       Impact factor: 5.270

4.  Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles.

Authors:  Zhan-Miao Yi; Cheng Wen; Ting Cai; Lu Xu; Xu-Li Zhong; Si-Yan Zhan; Suo-Di Zhai
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-17       Impact factor: 2.570

5.  The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder.

Authors:  Konstantinos N Fountoulakis; Lakshmi N Yatham; Heinz Grunze; Eduard Vieta; Allan H Young; Pierre Blier; Mauricio Tohen; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2020-04-23       Impact factor: 5.176

6.  Epilepsy With Suicide: A Bibliometrics Study and Visualization Analysis via CiteSpace.

Authors:  Yi Guo; Zheng-Yan-Ran Xu; Meng-Ting Cai; Wen-Xin Gong; Chun-Hong Shen
Journal:  Front Neurol       Date:  2022-01-17       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.